Check out this episode of Translation by our partners at 50 years about how our Founders, Nick Goldner and Chris Bulow, went from getting PhDs studying antibiotic resistance to starting a company whose sole mission is to develop novel therapeutics for cancer patients who suffer from treatment-resistant cancer.
Episode Summary: Evolution is happening even at the cellular scale. Whether it’s a virus, a bacterial pathogen, or a cancer cell, disease-causing agents are responding to the therapies we throw at them, updating their genes and molecular pathways to resist death. As a trained microbiologist, Nick Goldner and his co-founder Chris Bulow spent their years in grad school using -omics data to overcome antibiotic resistance in bacteria which led to their first company Viosera. As they struggled with the harsh realities of the antibiotics market, they stumbled upon the connection between bacterial and cancer resistance mechanisms. With this, they started resistanceBio which combines sophisticated tumoroids, intense patient sampling, and multi-omics to mimic the evolution of real tumors and ultimately find therapies that are irresistible.